(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 September 2022 (09.09.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/184755 A1

(51) International Patent Classification:
C07D 405/14 (2006.01) *A61P 29/00* (2006.01)
A61P 1/00 (2006.01) *A61P 35/00* (2006.01)
A61P 9/00 (2006.01) *A61P 37/00* (2006.01)
A61P 13/12 (2006.01) *A61K 31/4192* (2006.01)
A61P 27/02 (2006.01)

(21) International Application Number:
PCT/EP2022/055224

(22) International Filing Date:
02 March 2022 (02.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2021/055348
03 March 2021 (03.03.2021) EP

(71) Applicant: **IDORSIA PHARMACEUTICALS LTD** [CH/CH]; Hegenheimermattweg 91, 4123 Allschwil (CH).

(72) Inventors: **BOLLI, Martin**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). **GATFIELD, John**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). **GRISOSTOMI, Corinna**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). **REMEN, Lubos**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). **SAGER, Christoph**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). **ZUMBRUNN, Cornelia**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH).

(74) Agent: **VELKER, Jörg**; Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: TRIAZOLYL-METHYL SUBSTITUTED ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES



Formula (I)

(57) Abstract: The present invention relates to Galectin-3 inhibitors of Formula (I) and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds, and their medical uses.

WO 2022/184755 A1